Mirabegron in Overactive Bladder and Its Role in Exit Strategy After Botulinum Toxin Treatment in Children.

ABSTRACT:

Purpose

Mirabegron is a recent addition to the management options of overactive bladder (OAB) in children. The purpose of this study was to ascertain the role of Mirabegron in the treatment algorithm of therapy-resistant OAB especially after botulinum toxin.

Methods

Case notes of all children receiving Mirabegron between July 2017 and February 2020 were reviewed.

Results

Forty one children (21 females, 20 males), mean age 12.6 [8-17] years old, commenced Mirabegron: 35 idiopathic OAB, 6 neuropathic OAB. The mean duration of treatment was 20.7 [3-45] months. In total 24 (59%) had Mirabegron after partial/no response to anticholinergics, and 17 (41%) patients had Mirabegron subsequent to botulinum toxin A (BtA) as an exit strategy. In total 35 (85%) patients had combina

SUBMITTER: Tan DJY 

PROVIDER: S-EPMC8894583 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature